ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2434

Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Abstract Number: 2435

Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews
Abstract Number: 2436

Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
Abstract Number: 2437

Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Abstract Number: 2438

SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Abstract Number: 2439

Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Abstract Number: 2440

Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Abstract Number: 2441

Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Abstract Number: 2442

Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Abstract Number: 2443

Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
Abstract Number: 2444

Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
Abstract Number: 2445

Achievement of Treat to Target Measures With Upadacitinib in Patients With Systemic Lupus Erythematosus: Phase 2 Randomized SLEek Clinical Trial Results
Abstract Number: 2446

Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Reports
Abstract Number: 2447

Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab
Abstract Number: 2448

Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].